| Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy. | |
| | |
MedLine Citation:
|
PMID: 20929291 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Purpose: At least one-year follow-up of a case series of young Stevens-Johnson syndrome (SJS) patients with cicatrizing ocular surface disease and recurrent inflammation (SJS-RI) treated with systemic humanized monoclonal antibody (daclizumab). Methods: Five patients (median age 16 yr; range 8-34 yr) with SJS, with recurrent inflammation refractory to conventional immunotherapy, were enrolled in a prospective non-randomized case series study. Inclusion criteria were patients with SJS and ocular cicatrizing inflammatory disease with severe visual impairment, using topical or systemic anti-inflammatory and/or immunomodulatory drugs without clinical improvement resulting in persistent inflammation (SJS-RI). Treatment with Daclizumab 1 mg/Kg (intravenous) was scheduled in three cycles. First cycle with concomitant immunotherapy: a total of 5 doses, with 14 days interval between them (total of this cycle: 10 weeks). Second cycle: interval was increased to 3 weeks; the patients received 2 doses (the second cycle had a total of 6 weeks). Third cycle: maintenance phase with 4 weeks interval between each application, until at least 12 months of the total follow up. After the first cycle (5th dose), the patients were kept with preservative-free lubricants and systemic doxycycline. Results: Control of ocular inflammation was observed at a median of 8 weeks (range 6-10 weeks) in all patients, with relapses in two patients at 20-36 weeks. Relapses were controlled with topical steroids at a median of 10 days, and within 2 weeks the steroids were tapered for both patients. Conclusion: In this small case series, daclizumab demonstrated to play a beneficial role in the control of the inflammatory process of the recurrent inflammation in SJS, refractory to conventional immunomodulatory therapy. |
| | |
Authors:
|
Vanessa M B Fiorelli; Paulo E C Dantas; Allen T Jackson; M Cristina Nishiwaki-Dantas |
Publication Detail:
|
Type: Journal Article Date: 2010-10-07 |
Journal Detail:
|
Title: Current eye research Volume: 35 ISSN: 1460-2202 ISO Abbreviation: Curr. Eye Res. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8104312 Medline TA: Curr Eye Res Country: England |
Other Details:
|
Languages: eng Pagination: 1057-62 Citation Subset: IM |
Affiliation:
|
Florida Eye Research and Surgical Therapy Institute (FERST Eye Institute), Daytona Beach, Florida, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Organ-specific tubular and collagen-based composite scaffolds.
Next Document: Vascular basement membrane thickening in diabetic retinopathy.